vTv Therapeutics (VTVT) Interest Coverage Ratio (2014 - 2026)
vTv Therapeutics (VTVT) posted Interest Coverage Ratio of 1.12 for Q1 2026, up 102.78% sequentially from 40.44 in Q4 2025, and up 102.23% YoY from 0.55 in Q1 2025.
vTv Therapeutics (VTVT) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
vTv Therapeutics has reported Interest Coverage Ratio for 13 years, with the latest figure at 1.12 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 102.23% year-over-year to 1.12 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.15 (up 99.92% YoY) and the FY2025 annual result came in at 0.65, up 7.89% from the prior year.
- Interest Coverage Ratio advanced to 1.12 in Q1 2026 per VTVT's latest filing, from 40.44 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 1.12 in Q1 2026 and troughed at 2446.0 in Q4 2024.
- A 5-year average of 435.39 and a median of 26.11 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2025 and 2026: Interest Coverage Ratio slumped 7300.17% in 2025, then jumped 102.23% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 1057.17 in 2022, then jumped by 36.39% to 672.43 in 2023, then tumbled by 263.76% to 2446.0 in 2024, then surged by 98.35% to 40.44 in 2025, then jumped by 102.78% to 1.12 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.12, 40.44, and 2139.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - | -0.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.78 |
| Mar 31, 2026 | 1.12 |
| Dec 31, 2025 | -40.44 |
| Sep 30, 2025 | -2,139.80 |
| Mar 31, 2025 | -50.41 |
| Dec 31, 2024 | -2,446.00 |
| Sep 30, 2024 | -28.92 |
| Jun 30, 2024 | -26.11 |
| Mar 31, 2024 | -17.48 |
| Dec 31, 2023 | -672.43 |
| Sep 30, 2023 | -12.81 |
| Jun 30, 2023 | -17.09 |
| Dec 31, 2022 | -1,057.17 |
| Sep 30, 2022 | -9.02 |
| Jun 30, 2022 | -5.78 |
| Mar 31, 2022 | -8.51 |
| Dec 31, 2021 | -1,851.50 |
| Sep 30, 2021 | -1.80 |
| Jun 30, 2021 | -4.89 |
| Mar 31, 2021 | -15.56 |